PSA stands for prostate-specific antigen, an important protein produced by the prostate gland that plays a key role in screening for prostate cancer. In this article, we’ll explore what PSA means, how PSA tests work, and the latest developments in using PSA and other methods to detect and treat prostate cancer.
What is PSA?
Prostate-specific antigen (PSA) is a protein produced by both cancerous and noncancerous tissue in the prostate gland. PSA is mostly found in semen, but small amounts also circulate in the blood. A PSA blood test measures the level of prostate-specific antigen in a man’s bloodstream.
As men age, it’s normal for PSA levels to rise gradually. However, elevated PSA levels can sometimes indicate the presence of prostate cancer or other prostate conditions. That’s why PSA tests are commonly used as an initial screening tool for prostate cancer in men, typically starting around age 50.
How PSA Tests Work
A PSA test involves a simple blood draw that is then analyzed in a laboratory. The results show the level of PSA detected in nanograms per milliliter (ng/mL) of blood. Generally, PSA levels under 4 ng/mL are considered normal, while levels over 10 ng/mL may indicate a higher risk of prostate cancer. However, there is no universally-agreed upon cutoff point between normal and abnormal PSA levels.
It’s important to note that PSA tests alone cannot diagnose prostate cancer. Elevated PSA levels can be caused by other factors like:
– Benign prostatic hyperplasia (enlarged prostate)
– Prostatitis (inflammation of the prostate)
– Recent ejaculation
– Certain medications
– Aging
If a PSA test comes back elevated, doctors will typically recommend additional tests like a digital rectal exam, prostate biopsy, or imaging studies to determine if cancer is present.
Benefits and Limitations of PSA Screening
PSA testing has been widely used for prostate cancer screening since the 1990s. Some key benefits include:
– Allows detection of prostate cancer before symptoms develop
– May catch prostate cancer at earlier, more treatable stages
– Can monitor PSA levels over time to detect changes
However, PSA screening also has some limitations to consider:
– Can lead to overdiagnosis of slow-growing cancers that may never cause problems
– May result in unnecessary biopsies or treatments
– Does not distinguish between aggressive and non-aggressive cancers
– Can produce false positive or false negative results
Due to these limitations, medical organizations have differing guidelines on PSA screening. Men should discuss the pros and cons with their doctor to make an informed decision about PSA testing.
Treatment Advances for Prostate Cancer
For men diagnosed with prostate cancer, treatment options continue to improve. Some notable recent developments include:
– Targeted therapies that attack specific genetic mutations in prostate cancer cells
– Immunotherapy drugs that help the immune system fight prostate cancer
– More precise radiation therapy techniques that reduce side effects
– New hormone therapies for advanced prostate cancer
Additionally, a recent study found that regular exercise can reduce the risk of death from prostate cancer by up to 35%. Maintaining a healthy lifestyle remains one of the best ways to reduce prostate cancer risk.
When to Get Your PSA Checked
Most medical organizations recommend that men discuss PSA screening with their doctor starting around age 50. However, men at higher risk of prostate cancer, including African American men and those with a family history, may want to start the conversation earlier, around age 40-45.
Factors to consider when deciding on PSA screening include:
– Age and overall health
– Family history of prostate cancer
– Race/ethnicity (African American men are at higher risk)
– Symptoms like difficulty urinating
– Personal preferences regarding testing and potential treatment
The American Cancer Society emphasizes that the decision to get a PSA test should be an individual one made between a man and his healthcare provider after discussing the uncertainties, risks, and potential benefits.
